Academy Rebrands to Champion Geroscience, Combat Aging Hype

NEW YORK, NY – May 07, 2026 – In a strategic move to cut through the noise of the booming anti-aging market, a prominent scientific body today announced it is sharpening its identity. The Academy for Health and Lifespan Research (AHLR) has officially become the Academy of Geroscience, a name change intended to plant a flag for scientific rigor in a field often characterized by inconsistent definitions and commercial hype.

The rebranding marks a deliberate effort to distinguish the evidence-based study of aging biology from the broader, often nebulous, concepts of “longevity” and “healthspan.” The organization, a convener of leading scientists and clinicians, argues that these popular terms are frequently used without a firm scientific foundation, creating confusion for the public, policymakers, and even researchers.

“The field is at an inflection point,” said Dr. Nir Barzilai, President of the Academy and a renowned aging researcher. “There is extraordinary promise in the science of aging, but also increasing noise. To realize that promise, we must elevate awareness of geroscience as a distinct, evidence-based field and ensure that research on healthspan, longevity, and aging biology is grounded in scientific rigor.”

From Longevity to Geroscience: A Push for Precision

The Academy’s new name champions a specific discipline: geroscience. Unlike the general pursuit of a longer life, geroscience is an interdisciplinary field focused on a core hypothesis: that the biological processes of aging are the single greatest risk factor for most chronic diseases, including heart disease, cancer, and Alzheimer's. By understanding and targeting these fundamental mechanisms, geroscience aims not just to extend lifespan, but to prolong healthspan—the period of life spent in good health, free from debilitating illness.

This approach represents a paradigm shift from traditional medicine, which typically treats diseases one by one as they appear. Instead, geroscientists seek interventions that could delay or prevent a host of age-related conditions simultaneously by targeting aging itself. This focus aligns with the work of major research bodies like the National Institute on Aging (NIA) and the American Federation for Aging Research (AFAR), which have long advocated for studying the biology of aging as a path to preventing disease.

Following a year-long evaluation, the Academy concluded that the widespread use of terms like “longevity” had diluted their scientific meaning. The rebranding is a direct response, intended to establish a clear, scientifically grounded identity for the field and its practitioners.

A Stand Against the ‘Longevity Wild West’

The Academy’s move can be seen as an attempt to bring order to what some describe as the “longevity wild west”—a rapidly growing, multi-billion-dollar market filled with products and therapies making bold anti-aging claims, often with little to no robust scientific backing.

The “noise” Dr. Barzilai referred to includes a vast array of consumer-facing products. For instance, supplements containing NAD+ precursors like NMN and NR are widely marketed as longevity enhancers, yet large-scale human studies confirming their effectiveness and long-term safety are conspicuously absent. Experts caution that while NAD+ is vital for cellular function, there is no conclusive evidence that taking it in supplement form extends human life.

Similarly, unregulated stem cell clinics offer expensive anti-aging treatments, leveraging the language of regenerative medicine to attract clients despite a lack of FDA approval or clinical evidence for such applications. This phenomenon, which some critics call “scienceploitation,” capitalizes on public hope while posing potential health risks.

Even metrics used to quantify aging, such as “biological age clocks,” are often presented with a certainty that belies their current limitations. While these epigenetic tests are valuable research tools, their precision for individual diagnosis is still under development, and some companies have been criticized for marketing them with exaggerated claims about reversing age.

The Academy’s rebrand is a clear signal that it intends to serve as a trusted authority, helping to distinguish credible science from such misinformation.

The Power of a Name: Shaping Research and Investment

Founded in 2019, the Academy has established itself as a collective of elite researchers dedicated to advancing the field. Its leadership includes prominent figures like Dr. Barzilai, who directs the Institute for Aging Research at the Albert Einstein College of Medicine and is leading the landmark TAME (Targeting Aging with Metformin) study. This trial aims to prove that a single drug can delay the onset of multiple age-related diseases, a cornerstone concept in geroscience.

With this deep scientific credibility, the name change is more than symbolic. “This is more than a name change,” noted Risa Starr, the Academy’s Executive Director. “It’s a statement of purpose – to bring clarity to the field and ensure aging research is guided by scientific integrity and delivers real-world impact.”

This statement of purpose is likely to reverberate throughout the longevity ecosystem. For biotech companies focused on rigorous, FDA-approved therapeutics—such as Altos Labs, Calico Life Sciences, and Unity Biotechnology—the Academy’s emphasis on geroscience provides validation. For investors and venture capitalists, it offers a clearer framework for distinguishing promising, evidence-based ventures from more speculative ones.

By promoting a unified, scientifically rigorous identity, the Academy of Geroscience aims to steer public conversation, policy decisions, and funding toward research that holds the most promise for transforming human health. The organization will continue to convene global leaders and publish consensus insights to accelerate progress, now under a banner that leaves no room for ambiguity. By planting a flag for geroscience, the Academy is not just changing its name; it is drawing a clear line in the sand, challenging the entire field to prioritize scientific integrity on the path to a healthier, longer life.